CDC’s ACIP issued Interim recommendation for allocating initial supplies of COVID-19 vaccine
On Dec. 3, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended, as interim guidance, that both 1)…
-
-
Biotechnology | Diagnostics | Disease | Infectious Disease | Medicine | Non-Profit Research | Therapeutics
University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific Impact
On Dec. 2, 2020, the University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific…
-
BD to invest $12 billion in pre-fillable syringe manufacturing capacity over next four years
On Dec. 2, 2020, BD (Becton, Dickinson) announced plans to invest approximately $1.2 billion over a 4-year period…
-
Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
-
Roche received FDA Emergency Use Authorization for new test to measure level of SARS-CoV-2 antibodies
On Dec. 2, 2020, Roche announced that its Elecsysﾮ Anti-SARS-CoV-2 S antibody test had received Emergency Use Authorization…
-
Oxford Immunotec signed distributor agreement with RIKEN Genesis for T-SPOT Discovery SARS-CoV-2 Kit in Japan
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
-
Lilly announced 650,000 additional doses of COVID-19 neutralizing antibody bamlanivimab purchased by US government
On Dec. 2, 2020, Eli Lilly announced that the U.S. government had purchased 650,000 additional doses of the…
-
Codex DNA released new synthetic genomes for the fight against COVID-19
On Dec. 2, 2020, Codex DNA announced the release of seven new synthetic SARS-CoV-2 genomes for use in…
-
UK medicines regulator approved first UK COVID-19 vaccine
On Dec. 2, 2020, the first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, was given approval for…
-
Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…
-
VBI Vaccines announced submission of BLA to FDA for 3-antigen prophylactic Hepatitis B vaccine
On Dec. 1, 2020, VBI Vaccines announced the submission of a Biologics License Application (BLA) to the FDA…
-
US Department of Defense awarded $50 million in university research equipment award
On Dec. 1, 2020, the U.S. Department of Defense announced awards to 150 university researchers totaling $50 million…
-
FDA approved first PSMA-targeted PET imaging drug for men with prostate cancer
On Dec. 1, 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) ﾖ the first drug for…
-
Experimental vaccine for deadly tickborne virus effective in cynomolgus macaques
On Nov. 25, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
-
Novavax announced COVID-19 vaccine clinical development progress
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
-
Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
-
Jaguar Health announced development of Crofelemer for inflammatory diarrhea, with ‘Long-Hauler’ COVID-19 patients
On Nov. 30, 2020, Jaguar Health subsidiary, Napo Pharmaceuticals, announced that Jaguar and Napo are planning to develop…
-
NIH announced restructured HIV clinical trials networks
On Nov. 30, 2020, The National Institute of Allergy and Infectious Diseases (NIAID) announced the clinical investigators and…
-
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, a City of Hope investigational vaccine produced strong protective immunity against SARS-CoV-2, including neutralizing antibodies…
-
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
-
Biotechnology | COVID-19 | Therapeutics | WHO
Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19
On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…
-
Lonza expanded development and manufacturing aapabilities at Bend facility
On Nov. 30, 2020, Lonza announced $10 million investment in its Bend, Oregon facility. Originally known as Bend…
-
Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
-
DARPA and JPEO awarded contract to SmartPharm for development of rapid COVID-19 countermeasure,
On Nov. 27, 2020, SmartPharm Therapeutics, a wholly-owned subsidiary of Sorrento Therapeutics, announced that it had been awarded…
-
COVID-19 | USDA | Veterinary
First case of SARS-CoV-2 in mink confirmed in Oregon
On Nov. 27, 2020, the U.S. Department of Agriculture (USDA) announced that it had confirmed cases of SARS-CoV-2…
-
NIAID announced fourth iteration of COVID-19 treatment trial was underway
On Nov. 25, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
-
RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
-
University of Saskatchewan research team sequenced the genomes for 15 wheat varieties
On Nov. 25, 2020, a University of Saskatchewan research team announced it had sequenced the genomes for 15…
-
AIM ImmunoTech announced patient dosed in study of Ampligen as combo treatment for patients with cancer and COVID-19
On Nov. 25, 2020, AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Centerﾒs Phase 1/2a study evaluating the…
-
Altimmune announced submission of Investigational NDA for AdCOVIDﾙ a single-dose intranasal COVID-19 vaccine
On Nov. 25, 2020, Altimmune announced that it had submitted an Investigational New Drug (IND) application to the…
